Sulforaphane Treatment of Stress Urinary Incontinence Via the Nrf2-ARE Pathway in a Rat Model

Xiang Wan; Chong Liu; Yanbo Chen; Meng Gu; Zhikang Cai; Qi Chen; Zhong Wang

doi:10.1159/000485880

Sulforaphane Treatment of Stress Urinary Incontinence Via the Nrf2-ARE Pathway in a Rat Model

Xiang Wan, Chong Liu, Yanbo Chen, Meng Gu, Zhikang Cai, Qi Chen, Zhong Wang

In: Cellular Physiology and Biochemistry · 2017 · vol. 44(5) , pp. 1912–1922 · doi:10.1159/000485880 · PMID:29224018 · W2772220123

article OA: gold CC0

📄 Open PDF View on OpenAlex View on PubMed View at publisher

⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-08-02 ⓘ

Sulforaphane treatment in a rat model of stress urinary incontinence reduced oxidative stress, decreased apoptosis, and activated the Nrf2-ARE pathway, improving urethral sphincter muscle morphology and function.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

BACKGROUND/AIMS: To explore the effect of sulforaphane (SFN) treatment in rats through the induction of Stress Urinary Incontinence (SUI) via the Nrf2-ARE pathway. METHODS: A total of 18 female rats (Sprague-Dawley) were assigned to three groups: a control group, an SUI group, and an SUI+SFN group (six rats per group). Rats in the treatment groups were induced via postpartum vaginal balloon dilation and bilateral ovariectomy. Rats in the SUI+SFN group were treated via intraperitoneal injection once per day for a total of one month. Urethral sphincter muscle histological was observed by HE and Masson staining. Peak voiding pressure and interval of micturition were measured by cystometry. Oxidative stress markers and protein expression in the Nrf2-ARE pathway were examined by immunohistochemical staining and western blotting. RESULTS: Prolonged micturition interval and higher peak voiding pressure were observed in the SUI+SFN group. Disturbance of muscle morphology was ameliorated, muscle content was elevated, and collagen content was restrained in response to SFN treatment. The SOD, GSH-Px, and CAT activities were elevated in the SUI+SFN group compared to those in the control group. The level of cell apoptosis was decreased in SUI rats after SFN treatment; however, apoptosis was mainly located in the urethral mucosa instead of the muscle layer. SFN reduced the Bax/Bcl-2 expression ratio. Nrf2 and Nrf2 target antioxidant proteins were elevated in the SFN group. CONCLUSIONS: SFN was effective for SUI treatment via decreasing oxidative stress and activating the Nrf2-ARE pathway.

My notes (saved in your browser only)

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

References (40)

doi:10.1016/s0140-6736(06)67925-7 via openalex
doi:10.1016/j.eururo.2009.03.020 via openalex
doi:10.1016/s0022-5347(01)62074-3 via openalex
doi:10.1016/s0140-6736(99)02588-x via openalex
doi:10.1016/j.phrs.2014.10.004 via openalex
doi:10.1016/j.freeradbiomed.2009.07.035 via openalex
doi:10.1016/s0029-7844(99)00263-x via openalex
doi:10.1111/j.1532-5415.1998.tb02469.x via openalex
doi:10.1038/nrdp.2017.43 via openalex
doi:10.1016/j.freeradbiomed.2015.05.028 via openalex
doi:10.1016/s0022-5347(05)64915-4 via openalex
doi:10.1016/0378-4274(95)03553-2 via openalex
doi:10.3390/molecules190710074 via openalex
doi:10.1159/000132690 via openalex
doi:10.1073/pnas.94.19.10367 via openalex
W2404514393 via openalex
doi:10.3109/14653240903350265 via openalex
doi:10.1016/j.ejogrb.2012.04.012 via openalex
doi:10.5489/cuaj.79 via openalex
doi:10.1016/j.yjmcc.2013.01.008 via openalex
doi:10.1097/mou.0b013e3283476eb5 via openalex
doi:10.1155/2014/280204 via openalex
doi:10.1016/j.addr.2014.10.018 via openalex
doi:10.1152/ajpendo.00702.2013 via openalex
doi:10.1155/2014/314846 via openalex
doi:10.1124/jpet.111.190132 via openalex
doi:10.1016/j.eururo.2008.02.027 via openalex
doi:10.1152/ajpregu.00010.2003 via openalex
doi:10.1016/s0022-5347(05)66151-4 via openalex
doi:10.1016/j.phrs.2009.11.009 via openalex
doi:10.7326/0003-4819-148-6-200803180-00211 via openalex
doi:10.3791/3981 via openalex
doi:10.1152/japplphysiol.00744.2014 via openalex
doi:10.1016/j.juro.2008.07.020 via openalex
doi:10.1016/j.juro.2015.10.117 via openalex
doi:10.1016/j.jnutbio.2016.05.004 via openalex
doi:10.1155/2016/7598294 via openalex
doi:10.1186/1741-7015-10-94 via openalex
doi:10.1016/s0002-9378(99)70211-5 via openalex
doi:10.1111/j.1464-410x.2008.07582.x via openalex

SciLite annotations

chemicals 2

sulforaphane sulforaphane

organisms 5

zitter rats rattus sp. rattus sp. rattus sp. rattus sp.

Source provenance

openalex: last seen: 2026-05-10T10:25:42.067697+00:00
scilite: last seen: 2026-05-18T04:57:49.680383+00:00

License: CC0 · commercial use OK

[1] doi:10.1016/s0140-6736(06)67925-7 via openalex

[2] doi:10.1016/j.eururo.2009.03.020 via openalex

[3] doi:10.1016/s0022-5347(01)62074-3 via openalex

[4] doi:10.1016/s0140-6736(99)02588-x via openalex

[5] doi:10.1016/j.phrs.2014.10.004 via openalex

[6] doi:10.1016/j.freeradbiomed.2009.07.035 via openalex

[7] doi:10.1016/s0029-7844(99)00263-x via openalex

[8] doi:10.1111/j.1532-5415.1998.tb02469.x via openalex

[9] doi:10.1038/nrdp.2017.43 via openalex

[10] doi:10.1016/j.freeradbiomed.2015.05.028 via openalex

[11] doi:10.1016/s0022-5347(05)64915-4 via openalex

[12] doi:10.1016/0378-4274(95)03553-2 via openalex

[13] doi:10.3390/molecules190710074 via openalex

[14] doi:10.1159/000132690 via openalex

[15] doi:10.1073/pnas.94.19.10367 via openalex

[16] W2404514393 via openalex

[17] doi:10.3109/14653240903350265 via openalex

[18] doi:10.1016/j.ejogrb.2012.04.012 via openalex

[19] doi:10.5489/cuaj.79 via openalex

[20] doi:10.1016/j.yjmcc.2013.01.008 via openalex

[21] doi:10.1097/mou.0b013e3283476eb5 via openalex

[22] doi:10.1155/2014/280204 via openalex

[23] doi:10.1016/j.addr.2014.10.018 via openalex

[24] doi:10.1152/ajpendo.00702.2013 via openalex

[25] doi:10.1155/2014/314846 via openalex

[26] doi:10.1124/jpet.111.190132 via openalex

[27] doi:10.1016/j.eururo.2008.02.027 via openalex

[28] doi:10.1152/ajpregu.00010.2003 via openalex

[29] doi:10.1016/s0022-5347(05)66151-4 via openalex

[30] doi:10.1016/j.phrs.2009.11.009 via openalex

[31] doi:10.7326/0003-4819-148-6-200803180-00211 via openalex

[32] doi:10.3791/3981 via openalex

[33] doi:10.1152/japplphysiol.00744.2014 via openalex

[34] doi:10.1016/j.juro.2008.07.020 via openalex

[35] doi:10.1016/j.juro.2015.10.117 via openalex

[36] doi:10.1016/j.jnutbio.2016.05.004 via openalex

[37] doi:10.1155/2016/7598294 via openalex

[38] doi:10.1186/1741-7015-10-94 via openalex

[39] doi:10.1016/s0002-9378(99)70211-5 via openalex

[40] doi:10.1111/j.1464-410x.2008.07582.x via openalex